{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06143631",
            "orgStudyIdInfo": {
                "id": "23-39255"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01HD112465",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01HD112465"
                }
            ],
            "organization": {
                "fullName": "University of California, San Francisco",
                "class": "OTHER"
            },
            "briefTitle": "Prescription of Letrozole for Uterine Myoma",
            "officialTitle": "Letrozole for Treatment of Uterine Fibroids: A Randomized, Placebo-Controlled Trial",
            "acronym": "PLUM",
            "therapeuticArea": [
                "Other"
            ],
            "study": "prescription-of-letrozole-for-uterine-myoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-01-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-15",
            "studyFirstSubmitQcDate": "2023-11-15",
            "studyFirstPostDateStruct": {
                "date": "2023-11-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of California, San Francisco",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size."
        },
        "conditionsModule": {
            "conditions": [
                "Leiomyoma, Uterine",
                "Leiomyoma",
                "Fibroid",
                "Fibroid Uterus"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Letrozole",
                    "type": "EXPERIMENTAL",
                    "description": "Oral letrozole 2.5mg/day",
                    "interventionNames": [
                        "Drug: Letrozole 2.5mg"
                    ]
                },
                {
                    "label": "Placebo and Letrozole",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo capsule for 12 weeks; Oral letrozole 2.5mg/day for 12 weeks",
                    "interventionNames": [
                        "Drug: Letrozole 2.5mg",
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Letrozole 2.5mg",
                    "description": "Oral letrozole 2.5mg/day",
                    "armGroupLabels": [
                        "Letrozole",
                        "Placebo and Letrozole"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Placebo capsule",
                    "armGroupLabels": [
                        "Placebo and Letrozole"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Uterine leiomyoma-related symptom severity over 12 weeks of treatment",
                    "description": "Change in Uterine Fibroid Symptoms Quality of Life (UFS-QOL) Symptom Severity Scale (SSS) score \\[Range 8-40 with higher score indicating worse symptoms and worse outcomes\\]",
                    "timeFrame": "Baseline to 12 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Uterine leiomyoma-related quality of life over 12 weeks of treatment",
                    "description": "Change in Uterine Fibroid Symptoms Quality of Life (UFS-QOL) Health-Related QOL component score \\[Range 29-145 points, with higher score indicating better QoL and better outcomes\\]",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Total leiomyoma volume over 12 weeks of treatment",
                    "description": "Change in total leiomyoma volume based on pelvic ultrasound measurements",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Total uterine volume over 12 weeks of treatment",
                    "description": "Change in total uterine volume based on pelvic ultrasound measurements",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Symptoms of heavy menstrual bleeding",
                    "description": "Change in symptoms of heavy menstrual bleeding based on a modified Menstrual Bleeding Questionnaire (MBQ) score \\[Range 0-48 with higher MBQ score indicating worse symptoms and a negative impact on quality of life\\]",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Improvement in Sexual Functioning",
                    "description": "Change in pelvic problems-related sexual function as measured by the Sexual Health Outcomes in Women Questionnaire (SHOW-Q) Pelvic Problems Interference subscale score \\[Range 0-100 with higher scores indicating better sexual function\\]",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Symptoms of pelvic pain",
                    "description": "Change in pelvic pain severity/intensity \"on average\" (evaluated on a standard numerical rating scale of 0-10, lower rating indicating better outcomes and less pain)",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Symptoms of urogenital distress",
                    "description": "Change in distressing urogenital symptoms such as urinary frequency, urinary incontinence, and genital pain, as measured by Urogenital Distress Inventory-6 (UDI-6) \\[Range 0-100 with higher scores indicating higher disability/worse outcomes\\]",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Effect of letrozole on serum cholesterol levels",
                    "description": "Change in serum LDL cholesterol levels",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Effect of letrozole on serum estradiol levels",
                    "description": "Change in serum estradiol levels",
                    "timeFrame": "Baseline to 12 weeks"
                },
                {
                    "measure": "Effect of letrozole on frequency of hot flashes",
                    "description": "Change in frequency of vasomotor symptoms (hot flashes) as measured by the Hot Flush Rating Scale (HFRS) \\[no scale range but less # of reported hot flashes indicates better outcome\\]",
                    "timeFrame": "Baseline to 12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* At least 21 and less than 54 years of age (to focus on an adult, premenopausal population)\n* Female sex, based on sex identified on their birth certificate (no other gender requirements)\n* Have uterine leiomyomata that have been visualized on pelvic imaging (i.e., ultrasound or MRI) in the last 24 months\n* Report symptoms associated with leiomyomata such as heavy uterine bleeding, pelvic pressure or discomfort, urinary or bowel abnormalities, or dyspareunia for the past 3 months\n* Have at least moderate leiomyomata symptom burden, with UFS-QOL SSS score of 30 or higher at baseline\n* Has regularly-occurring menstrual periods of \u2264 14 days duration with a cycle of 21 to 38 days from the start of one menstrual period until the start of the next, by patient history for at least 3 months prior to screening\n* Agree to use a non-hormonal barrier method of contraception during the study period if at risk for pregnancy (any sexual activity with a non-sterile male partner)\n\nExclusion Criteria:\n\n* Screening pelvic imaging indicating any leiomyomata \u22658 cm in maximum diameter, or uterine size \u226514 cm in length (equivalent to 14 weeks gestation)-note that candidates who exclusively have prior clinical pelvic imaging 12-24 months ago will be excluded if imaging includes leiomyomata \u22657 cm in maximum diameter, or uterine size \u226513 cm in length, presuming leiomyoma growth of \u22651 cm per year\n* Screening pelvic imaging indicating only one, sole leiomyoma \\<2 cm in maximum diameter\n* Any submucosal leiomyoma that is \\<50% within uterine cavity (FIGO Type 0 or Type 1 leiomyomata)\n* Visit to the emergency room or hospitalization for leiomyoma symptoms in the last 12 weeks\n* Leiomyomata treated by surgery, radiologic procedure in the last 12 weeks; or plans to undergo any of the above in the next 24 weeks\n* Leiomyomata treated by GRNH agonist or antagonist in the last 12 weeks; or plans to use the above in the next 24 weeks\n* Currently pregnant or lactating, pregnant or lactating in the past 12 weeks, or planning to become pregnant in the next 24 weeks\n* Screening serum hemoglobin \\<8 g/dL, or history of blood transfusion in the last 12 weeks (indicating severe anemia)\n* Screening cholesterol lipid panel testing showing LDL cholesterol level \u2265 190 mg/dL (due to rare side effects over long-term use of aromatase inhibitors in postmenopausal women)\n* Screening serum estradiol level \\<30 pg/mL (consistent with postmenopausal status)\n* Age \u226545 years with irregularly timed, heavy bleeding that has not yet been evaluated by endometrial biopsy, or endometrial biopsy indicating hyperplasia or malignancy\n* History of osteoporosis (based on self-reported DEXA indicating bone mineral density Z-score \\< -2.0 at spine, total hip, or femoral neck; a prior fracture judged to be a fragility fracture; or self-reported use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, or denosumab for bone density loss)\n* History of severe liver disease (Child Pugh Class C cirrhosis), posing safety risks for use of letrozole\n* Current or prior history of breast cancer (given potential need to take letrozole for breast cancer treatment or secondary prevention)\n* Screening pelvic imaging indicating an Ovarian-Adnexal Reporting and Data System (O-RADS) category 3, 4, or 5 ovarian or adnexal lesion\n* Screening pelvic imaging concerning for other current cancer of the gynecologic, genitourinary or gastrointestinal system\n* Prior hypersensitivity or significant adverse reaction to letrozole or any aromatase inhibitor, or to an ingredient in the placebo capsule\n* Use of letrozole, other aromatase inhibitor, or selective estrogen receptor modulator (SERM) medications in the past 4 weeks, or existing plans to initiate one of these in the next 24 weeks\n* Use of oral, vaginal, or topical exogenous estrogen, progestin, or androgen therapy in the past 4 weeks; or injectable forms of the above in the past 12 weeks; or plans to initiate any of the above in the next 24 weeks\n* Use of medications with potential unsafe interactions with letrozole in the past 4 weeks (methadone, levomethadone, nintedanib, thalidomide), or plans to initiate these in the next 24 weeks\n* Any condition that, in the opinion of the investigators, would interfere with ability to complete study procedures, including acute or uncontrolled mental health condition, substance abuse, or inability to complete procedures in English (or Spanish, for sites that offer study assessments in Spanish)",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "21 Years",
            "maximumAge": "53 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Coordinator",
                    "role": "CONTACT",
                    "phone": "(510) 788-0545",
                    "email": "plumstudy@ucsf.edu"
                },
                {
                    "name": "Lisa Abinanti",
                    "role": "CONTACT",
                    "email": "lisa.abinanti@ucsf.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Vanessa Jacoby, MD, MAS",
                    "affiliation": "University of California, San Francisco",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Alison Huang, MD, MAS",
                    "affiliation": "University of California, San Francisco",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94115",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maria Tolentino",
                            "role": "CONTACT",
                            "email": "plumstudy@ucsf.edu"
                        },
                        {
                            "name": "Yulissa Oceguera-Barragan",
                            "role": "CONTACT",
                            "email": "plumstudy@ucsf.edu"
                        },
                        {
                            "name": "Vanessa L Jacoby, MD, MAS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Alison Huang, MD, MAS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "University of Mississippi Medical Center",
                    "status": "RECRUITING",
                    "city": "Jackson",
                    "state": "Mississippi",
                    "zip": "39216",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shauna Spencer",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Sheila Belk",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Kedra Wallace, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Elizabeth Lutz, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.29876,
                        "lon": -90.18481
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007889",
                    "term": "Leiomyoma"
                },
                {
                    "id": "D000047708",
                    "term": "Myofibroma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009379",
                    "term": "Neoplasms, Muscle Tissue"
                },
                {
                    "id": "D000018204",
                    "term": "Neoplasms, Connective and Soft Tissue"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009372",
                    "term": "Neoplasms, Connective Tissue"
                },
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10901",
                    "name": "Leiomyoma",
                    "asFound": "Leiomyoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25846",
                    "name": "Myofibroma",
                    "asFound": "Fibroids",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12166",
                    "name": "Myoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20350",
                    "name": "Neoplasms, Connective and Soft Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12317",
                    "name": "Neoplasms, Connective Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077289",
                    "term": "Letrozole"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000047072",
                    "term": "Aromatase Inhibitors"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000004965",
                    "term": "Estrogen Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1743",
                    "name": "Letrozole",
                    "asFound": "Cross-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25769",
                    "name": "Aromatase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M8114",
                    "name": "Estrogen Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30483",
                    "name": "Estrogen Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}